EMA CHMP gives positive recommendation to elranatamab for the treatment of relapsed or refractory myelomaAccess, MPE, Myeloma13 October 2023
EMA CHMP recommends non-renewal of marketing authorisation for Blenrep®Access, Myeloma22 September 2023
EMA recommends expansion of melphalan flufenamide (Pepaxti®) marketing authorisationAccess, Myeloma18 September 2023
European Commission approves talquetamab for the treatment of relapsed and refractory myelomaAccess, Myeloma22 August 2023
FDA grants talquetamab (TALVEY™) accelerated approval for relapsed or refractory myelomaAccess, Myeloma14 August 2023
Watch the recording of the EHA 2023 highlights webinarAL amyloidosis, MPE, Myeloma, Videos10 July 2023
